Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

54.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms. 
Via The Motley Fool
News headline image
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASD... 
Via StockStory
Topics Artificial Intelligence
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
Via Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Q4 2025 Revenue Beat and EPS Miss ↗
Via Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
Via Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a 'Decent Value' Candidate ↗
Via Chartmill
News headline image
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology. 
Via The Motley Fool
News headline image
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases. 
Via The Motley Fool
News headline image
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S. 
Via The Motley Fool
Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal ↗
Via Stocktwits
News headline image
2 Mid-Cap Stocks with Exciting Potential and 1 We Question
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
News headline image
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Reasons to Like BMRN (and 1 Not So Much)
BioMarin Pharmaceutical currently trades at $61.02 per share and has shown little upside over the past six months, posting a middling return of 3.5%. Does th... 
Via StockStory
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 17% year on year to $874.6 million. The company expects the... 
Via StockStory
Topics Earnings
News headline image
BioMarin Pharmaceutical Earnings: What To Look For From BMRN
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Monday after market close. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence Government World Trade
News headline image
Should You Buy BioMarin Pharmaceutical Before Feb. 18? ↗
There's no need to hurry in buying this biotech stock. 
Via The Motley Fool
Topics Earnings
News headline image
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Artificial Intelligence
News headline image
The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity
The first week of 2026 has signaled a tectonic shift in the global financial landscape, as a wave of multi-billion dollar acquisitions has effectively ended the deal-making drought of the previous two... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
10 Magnificent Stocks That Can Make You Richer in 2026 ↗
A new year brings new opportunities to grow your wealth on Wall Street. 
Via The Motley Fool
Topics Economy Stocks World Trade
News headline image
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the afternoon session after the stock's positive momentum continued as the company agreed to acquire Amicus Therapeutics... 
Via StockStory
News headline image
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 19% in the afternoon session after the company announced it agreed to acquire Amicus Therapeutics for approximately $4.8 billion... 
Via StockStory
Topics Economy
News headline image
Which stocks are gapping on Friday? ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
1 Oversold Stock Primed to Rebound and 2 That Underwhelm
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
News headline image
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
BioMarin Pharmaceutical (BMRN) presents a compelling value investment case, trading at a significant discount to its biotech peers while showing strong profitability, financial health, and growth... 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.